[1]肖 进,张新莉.醒脾祛湿汤治疗湿浊痹阻型胸痹心痛临床研究[J].陕西中医,2021,(4):463-466.[doi:DOI:10.3969/j.issn.1000-7369.2020.04.015]
　XIAO Jin,ZHANG Xinli.Clinical study on chest pain patients with Shizhuo Bizu type treated by Xingpi Qushi decoction[J].,2021,(4):463-466.[doi:DOI:10.3969/j.issn.1000-7369.2020.04.015]
点击复制

醒脾祛湿汤治疗湿浊痹阻型胸痹心痛临床研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2021年4期
页码:
463-466
栏目:
临床研究
出版日期:
2021-04-05

文章信息/Info

Title:
Clinical study on chest pain patients with Shizhuo Bizu type treated by Xingpi Qushi decoction
作者:
肖 进; 张新莉
(凉山彝族自治州中西医结合医院,四川 西昌 615000)
Author(s):
XIAO Jin; ZHANG Xinli
(Liangshan Yi Autonomous Prefecture Hospital of Integrated Traditional Chinese and Western Medicine,Xichang 615000,China)
关键词:
胸痹心痛;  醒脾祛湿汤;  湿浊痹阻型;  心绞痛;  心电图;  心率变异性
Keywords:
Chest pain;  Xingpi Qushi decoction;  Shizhuo Bizu type;  Angina pectoris;  Electrocardiogram;  Heart rate variability
分类号:
R 541.4
DOI:
DOI:10.3969/j.issn.1000-7369.2020.04.015
文献标志码:
A
摘要:
目的:观察醒脾祛湿汤治疗湿浊痹阻型胸痹心痛临床效果。方法:82 例胸痹心痛患者随机分为两组,对照组给予常规西药治疗,观察组联合醒脾祛湿汤口服治疗。对比两组治疗前后西雅图心绞痛量表评分、血生化指标(hs-CRP、Hcy)、心电图心率变异性(HF、LF),比较两组临床疗效、心电图疗效及不良反应。结果:两组治疗后西雅图心绞痛量表评分,HF、LF、LF/HF指标均明显升高(P<0.05),hs-CRP、Hcy水平均明显降低(P<0.05),且观察组改善均优于对照组(P<0.05); 两组治疗后观察组心电图总有效率和临床总有效率均明显高于对照组(P<0.05); 两组均未无明显不良反应。结论:醒脾祛湿汤联合西药治疗能够降低胸痹心痛患者血生化指标,改善心电图心率变异性,有助于缓解心痛症状。
Abstract:
Objective:To observe the effect of Xingpi Qushi decoction on the symptoms of heartache,electrocardiogram and the levels of hs-CRP and Hcy in chest pain patients with Shizhuo Bizu type.Methods:82 patients were selected 41 patients in the control group were given sublingual nitroglycerin tablets,oral aspirin enteric coated tablets,oral metoprolol tartrate sustained-release tablets and oral atorvastatin calcium tablets.41 patients in the observation group were given Xingpi Qushi decoction on the basis of the control group for 4 weeks.Before and after treatment,the scores of Seattle angina pectoris scale(physical activity limitation,stable state of angina pectoris,angina pectoris attack,treatment satisfaction and disease awareness),the indexes of blood biochemical [high sensitivity reactive protein(hs-CRP),homocysteine(Hcy)],the ECG heart rate variability [high frequency heart rate(HF),low frequency heart rate(LF)] were compared between the two groups,and the clinical effect,ECG effect and adverse reactions of the two groups were compared.Results:After treatment,the physical activity limitation,stable state of angina pectoris,angina pectoris attack,treatment satisfaction and disease awareness score,the index of HF,LF,LF/HF the two groups were significantly increased(P<0.05),which in the observation group were significantly higher than those in the control group(P<0.05).The serum levels of hs-CRP and Hcy of the two groups were significantly decreased(P<0.05),and the observation group was significantly lower than the control group(P<0.05).After treatment,the total effective rate of ECG in the observation group was 90.2%(37/41),which was significantly higher than 70.7%(29/41)in the control group(χ2=4.970,P<0.05); The total effective rate of the observation group was 92.7%(38/41),which was significantly higher than 73.2%(30/41)in the control group(χ2=5.513,P<0.05).There was no obvious adverse reactions occurred in the two groups during the treatment.Conclusion:The application of Xingpi Qushi decoction combined with western medicine can reduce the serum levels of hs-CRP and Hcy,improve the ECG heart rate variability index,which help to alleviate the symptoms of heartache and improve the clinical treatment effect.

参考文献/References:

[1] 季昭臣,胡海殷,杨丰文,等.益气活血类中成药治疗冠心病心绞痛的网状Meta 分析[J].中国中药杂志,2019,44(9):1927-1937.
[2] 邢小燕,翟向伟,范 辉,等.血府逐瘀汤联合西药治疗心血瘀阻型冠心病心绞痛疗效观察[J].陕西中医,2017,38(10):1368-1369.
[3] 朱 薇.通脉调脂方治疗冠心病稳定性心绞痛疗效及对患者血流变、VCAM-1及ICAM-1 影响的研究[J].陕西中医,2019,40(3):290-293.
[4] 鲁利甫,邱雪银,魏振国.当归四逆汤加减联合麝香保心丸治疗老年冠心病心绞痛疗效及对患者心电图、血清因子水平的影响[J].陕西中医,2019,40(5):587-590.
[5] 中华医学会心血管病分会,中华心血管病杂志编辑委员会.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206.
[6] 杨培均.实用中医心血管病诊疗学[M].北京:中国中医药出版社,2008:56-57.
[7] 佚 名.冠心病心绞痛及心电图疗效评定标准(中西医结合治疗冠心病心绞痛及心律失常座谈会,1979,上海)[J].中国药事,1987,1(2):71-74.
[8] 马春梅,叶道斌,毛积分,等.中青年冠状动脉粥样硬化危险因素分析[J].武警医学,2012,23(4):309-311.
[9] 中国中西医结合学会心血管病专业委员会血脂与动脉粥样硬化学组.动脉粥样硬化中西医结合诊疗专家共识[J].中国全科医学,2017,20(5):507-511.
[10] 任 涛,李枚娟,王 焱,等.动脉粥样硬化与炎症反应关系的研究进展[J].中国老年学杂志,2010,30(10):1464-1467.
[11] 刘淑玲,蔡海荣,陈燕虹,等.红花黄色素对动脉粥样硬化大鼠内皮功能、炎症反应、氧化应激的影响[J].中国老年学杂志,2019,39(18):4585-4588.
[12] 李向兵.冠心病患者hs-CRP水平与冠状动脉病变程度的相关性分析[J].临床合理用药,2018,11(11):157-158.
[13] 李轶男,王 萍,陈 晖.同型半胱氨酸与冠状动脉粥样硬化性心脏病关系的研究进展[J].中国老年多器官疾病杂志,2019,18(10):792-795.
[14] 徐向聪.老年冠心病患者血清hs-CRP、Hcy及sd-LDL与冠状动脉狭窄的相关性分析[J].国际医药卫生导报,2018,24(15):2318-2320.
[15] 王彬辉,章文红,张晓芬,等.苦杏仁苷提取工艺及药理作用研究新进展[J].中华中医药学刊,2014,32(2):381-384.
[16] 吕运权,张 恒.川芎和郁金防治冠心病的研究进展[J].中西医结合心脑血管病杂志,2019,17(7):1011-1013.
[17] 李 冀,李 想,高彦宇,等.中药石菖蒲研究进展[J].辽宁中医药大学学报,2019,21(10):13-17.
[18] 崔鹤蓉,王睿林,郭文博,等.茯苓的化学成分、药理作用及临床应用研究进展[J].西北药学杂志,2019,34(5):694-700.
[19] 李陈雪,杨玉赫,冷德生,等.枳壳化学成分及药理作用研究进展[J].辽宁中医药大学学报,2019,21(2):158-161.
[20] 张晓娟,左冬冬.白术化学成分及药理作用研究新进展[J].中医药信息,2018,35(6):101-106.

相似文献/References:

[1]彭艳斌,蔡虎志,陈青扬,等.从“阳化气阴成形”理论探讨枳实薤白桂枝汤治疗胸痹*[J].陕西中医,2020,(12):1787.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.028]
[2]孙 伟,孙秋月,徐 淼.养心平脉汤配合针灸治疗气阴两虚兼血瘀型胸痹心痛疗效及对患者中医症状、心电图指标的影响[J].陕西中医,2023,(9):1308.[doi:DOI:10.3969/j.issn.1000-7369.2023.09.036]
　SUN Wei,SUN Qiuyue,XU Miao.Effects of Yangxin Pingmai decoction combined with acupuncture and moxibustion on TCM symptoms and electrocardiogram indicators in treating chest stuffiness and pains(qi-yin deficiency and blood stasis type)[J].,2023,(4):1308.[doi:DOI:10.3969/j.issn.1000-7369.2023.09.036]

备注/Memo

备注/Memo:
基金项目:四川省科技计划项目(2019JDZH0035)
更新日期/Last Update: 2021-04-09